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Abstract
Cardiovascular diseases are the leading cause of morbidity and mortality in 
general population worldwide. There is an increasing significance of cardiovascular 
risk in the field of rheumatology, and accordingly, the evidence on the relation 
between immune system disorders and atherosclerosis has been substantially 
growing especially in last decades. Since novel immune and metabolic factors are 
considered to participate in pathogenesis of atherosclerosis and increased cardio-
vascular risk in rheumatic patients, they are getting to the forefront of the research. 
Since novel therapeutic approaches have improved survival of rheumatic patients, 
and decreased morbidity caused by rheumatic disease activity and damage, the 
significance of other comorbidities leading to premature mortality has arisen. 
Nevertheless, appropriate recommendations for the management of cardiovascular 
risk are still lacking. Recently, European League Against Rheumatism (EULAR) 
recommendations for management of the cardiovascular risk and comorbidities 
in patients with inflammatory arthropathies have been published. However, the 
cardiovascular management of these patients is still suboptimal. In addition, the 
situation in other orphan diseases such as idiopathic inflammatory myopathies, 
systemic sclerosis and others is even more uncertain and strongly requires further 
research. This chapter provides an overview of epidemiology, pathogenesis, clini-
cal manifestations, screening and management of atherosclerosis in patients with 
rheumatic diseases.
Keywords: atherosclerosis, rheumatic diseases, metabolic risk factors, management, 
therapy
1. Introduction
Cardiovascular diseases (CVDs) are estimated to be the leading cause of 
mortality and morbidity worldwide and are responsible for one-third of world’s 
population mortality [1]. Atherosclerosis (ATS), as the main cause of CVD, starts 
to develop early in the life and presents later with clinical manifestations depend-
ing on other circumstances. ATS is a multifactorial disease, in which the immune 
system and impairment of vascular system play a significant role. Inflammation, 
which can be triggered by infectious agents or by autoimmune reaction, wors-
ens and promotes atherogenesis by several mechanisms [2]. In addition to the 
immune system, other factors significantly participate in atherogenesis by 
facilitating the vascular damage, initiating the formation, progression and the 
rupture of atherosclerotic plaques leading to consequent clinical manifestation of 
ATS. So-called traditional risk factors include dysregulation of lipid and glucose 
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metabolism, arterial hypertension, and degeneration of vascular tissue caused by 
aging, smoking and hormonal factors [3].
It is well known that autoimmune diseases are accompanied by increased CV 
morbidity and mortality, caused by exacerbation of atherogenesis [2]. Traditional 
risk factors of ATS in general population such as dyslipidemia, glucose intolerance, 
arterial hypertension, etc. can explain only about 75% of CV manifestations in 
rheumatic patients [4]. In these patients, non-traditional risk factors associated 
with the systemic inflammatory disease apply [5].
Despite the significant improvement of the therapy of rheumatic diseases, the 
incidence of CVD in rheumatic patients remains increased compared to that in 
general population [6]. Both the CV risk and CVD manifestations differ among 
rheumatic diseases according to the characteristic pathogenetic mechanism, 
inflammation activity and other specific features of the rheumatic diseases [7]. CV 
risk in the more prevalent rheumatic diseases such as rheumatoid arthritis (RA) 
or systemic lupus erythematosus (SLE) is relatively best described. On the other 
hand, the situation is less clear in orphan connective tissue diseases such as systemic 
sclerosis (SSc), idiopathic inflammatory myopathies (IIM), primary Sjögren’s 
syndrome (pSS) and others.
The aim of this review chapter is to provide an overview and sum up the current 
knowledge on CV risk factors and the treatment options of ATS-related comorbidi-
ties in rheumatic diseases.
2. Cardiovascular risks in rheumatic diseases
Traditional CV risk factors play two roles in rheumatic patients: the first one 
as a trigger, the second as a consequence of the rheumatic disease activity [3]. 
Non-traditional risk factors are given by genetic and epigenetic factors, concurrent 
autoimmune inflammatory disorder and the specific features of each particular 
rheumatic disease (age of onset, duration, activity and the type of the disease) and 
other comorbidities, among others depression [8–10].
2.1 Metabolic syndrome and its association with immune disorders
Metabolic syndrome (MetS) is defined as a cluster of comorbidities and risk fac-
tors leading to CVDs and increasing the CV mortality and morbidity. MetS includes 
obesity and visceral adiposity, diabetes and insulin resistance (IR), arterial hyperten-
sion (AH) and dyslipidemia [11]. The matter of mutual interactions and cross-talk of 
immune and metabolic system has become the object of many studies in recent years. 
Immune-metabolic interactions are regulated by genetic factors, nutritional status 
and by intestinal microbiome. The imbalance of the immune and metabolic interac-
tions contributes to the occurrence and manifestation of rheumatic diseases [12].
The prevalence of MetS in general population is estimated to be 24–44% 
depending on the exact definition of the MetS and the studied population [11, 13], 
and increases in rheumatic patients and gout to as much as 36–42%, as was reported 
in studies comparing rheumatic patients to the healthy control population [13].
Different immune mechanisms have been reported to be implemented in the patho-
genesis of MetS, including pro-inflammatory cytokines, namely interleukin (IL)-1 and 
IL-12 family. These cytokines are included in the regulation of immune response and 
atherogenic damage, and in the differentiation of T helper cells (Th), which participate 
in the pathogenesis of both autoimmune disorders and CVDs [14, 15]. Cytokines of 
IL-23/IL-17 signaling pathway are increased in rheumatic diseases, and significantly 
participate in atherogenesis [16]. MetS is associated with increased oxidative stress, 
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which, among others, leads to the formation of oxidized phospholipids (oxPL) and 
contributes to pathogenesis of autoimmune disorders [13].
IR is not only closely related to MetS, but is also considered to act as a key 
pathogenic factor in MetS [13]. The definition describes IR as a decreased 
sensitivity and responsiveness of target organs to the action of insulin result-
ing in hyperinsulinemia [17]. As consequence, this metabolic disorder leads to 
glucotoxicity, lipotoxicity and inflammation, all of which participate in endothe-
lial damage and dysfunction [18]. The visceral fat tissue is considered to be the 
major locus of these unfavorable changes. Of note, CVDs, MetS and autoimmune 
disorders share common pathogenic mechanisms and mediators of inflammation 
and activity [13].
In recent years, study of microbiome has come to the forefront of interest. An 
imbalance of intestinal microbiota (dysbiosis) is characterized by a decrease of the 
number of beneficial intestinal bacteria and the overgrowth of potentially patho-
genic bacteria. This phenomenon accompanies metabolic disorders and contributes 
to the emergence of MetS, obesity and type 2 diabetes mellitus (T2DM) [19]. 
Impaired balance of the intestinal flora may also contribute to the development of 
autoimmune disorders. Several studies have demonstrated onset of inflammation 
induced by alterations in the gut microbiome. This could explain the relationship 
between the microbiome and systemic inflammatory response [20].
2.2 Obesity as an active contributor to inflammation
The definition of obesity is mostly based on the body mass index (BMI— 
values higher than 30 kg/m2). Obesity, as well as MetS, is a global health problem 
especially in developed countries. The prevalence has been constantly grow-
ing over the years and to date, it is estimated to be almost 40% in the general 
population [21, 22]. Nevertheless, the association of obesity and CVDs in the 
general population is not clear [23]. Some evidence even suggests better prog-
nosis for people with higher value of BMI [24]. However, there is a well-known 
correlation of obesity and increased risk of T2DM and coronary arterial disease 
(CAD), as well as a negative impact of obesity on other comorbidities including 
rheumatic diseases [23]. The immunomodulatory potential of adipose tissue and 
its ability to create an inflammatory environment of moderate activity could 
explain the effect of obesity as a risk factor for the development of some auto-
immune diseases [22, 25].
Adipose tissue not only consists of adipocytes and connective tissue cells, but 
also contains immune cells as well (T cells, eosinophils, B regulatory cells and 
macrophages) [26–28]. In individuals with normal BMI, the immune cells interact 
with adipocytes and maintain a non-inflammatory environment by produc-
tion of anti-inflammatory cytokines (IL-10, IL-4, IL-13) [27]. On the contrary, 
predominance of pro-inflammatory T helper (Th) type 1 and 17 cells and pro-
inflammatory type of macrophages has been found in increased adipose tissue 
mass of obese individuals [27, 29, 30]. These changes result in the production of 
pro-inflammatory molecules such as tumor necrosis factor (TNF) and IL-6, which 
are one of the crucial cytokines involved in the pathogenesis of several rheu-
matic diseases. Moreover, obesity leads to an altered expression of adipokines, 
multifunctional molecules produced by white adipose tissue cells and involved 
in the regulation of inflammatory and autoimmune processes [31, 32]. The MetS 
and secretion of pro-inflammatory adipokines can be associated with CVDs and 
autoimmune disorders [13].
Thus, obesity is not only a passive comorbidity, but can actively participate in 
the inflammatory process. According to the current evidence, obesity can negatively 
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affect the course of most rheumatic diseases, functional disability, quality of life 
and the overall prognosis [21, 22].
2.3 Dyslipidemia in autoimmune disorders
Dyslipidemia is one of the most common forms of metabolic disease in the general 
population and also a significant risk factor for atherogenic CVD. In the general popula-
tion, dyslipidemia is characterized by an increased level of total cholesterol (TC), 
low-density lipoproteins (LDLs), triglycerides (TGs) and a decreased level of high-
density lipoproteins (HDLs) [33]. Under normal circumstances, HDL (in normal serum 
levels) exerts an anti-atherogenic effect: it removes cholesterol particles from cells 
(especially macrophages in the artery wall) and from circulation; inhibits the migration 
of macrophages and the binding of monocytes to the endothelium, oxidation of LDL; 
promotes endothelial repair and improves endothelial function, and also exerts anti-
inflammatory and anti-apoptotic effects [34–36]. In systemic inflammation, HDL is 
converted into a dysfunctional form due to loss of anti-inflammatory and anti-oxidative 
proteins. The modification of apolipoprotein A1 (apo-A1) results in the inability of HDL 
to uptake LDL from macrophages and in the activation of pro-inflammatory pathways 
leading to increased risk of coronary artery involvement [35, 37].
Moreover, quantitative changes of lipidogram related to disease activity are 
often seen in rheumatic diseases. In RA patients, the levels of TC and LDL are lower 
than in general population. This so-called lipid paradox, best described in RA, is 
associated with an increased CV risk [37]. Decrease in levels of TC and LDL has 
been found to precede clinical manifestation of RA. Later, TC and LDL levels tend 
to increase after the initiation of immunosuppressive therapy and on the contrary, 
decline during the relapse of RA [38]. Therefore, the low levels of TC and LDL can 
be misinterpreted as a low CV risk factor when evaluated according to the scoring 
tools (e.g., Framingham risk score, Reynolds risk score, Systemic Coronary Risk 
Evaluation—SCORE) [39–41].
A small study in early RA patients reported non-significant, beneficial effect of 
methotrexate similar to that of tumor necrosis factor inhibitors (anti-TNF) on lipi-
dogram [42]. On the other hand, higher levels of TC, LDL and TG were described 
in patients with ankylosing spondylitis (AS) treated by anti-TNF compared to AS 
patients on nonsteroidal anti-inflammatory drug (NSAID) therapy. Nevertheless, 
results reported in a cross-sectional study do not allow for a generalized assessment 
of the influence of long-term anti-TNF therapy on lipidogram in AS [43].
Dyslipidemia is found in almost half of SLE patients, characterized by elevated 
levels of very-low density lipoprotein (VLDL) and TG. Increased levels of TC and 
TG are associated with two times increased risk of CVD [44]. In SSc, dyslipidemia 
is characterized by increased levels of lipoprotein A (LpA) and LDL and decreased 
levels of HDL and TC [45].
2.4 Role of immune system and autoantibodies in atherogenesis
The presence of immune cells in atherosclerotic plaques proves the participation 
of immune system in atherogenesis [46, 47]. These infiltrating immune cells are 
responsible for the promotion and exacerbation of ATS [48]. All the components 
of immune system are included in atherogenesis, while TNF and IL-1β are the most 
significant pro-inflammatory cytokines and mediators [1].
Damage of endothelium is the first step in atherogenesis. Particles circulating 
in the blood penetrate the damaged endothelial barrier into subendothelial layer 
via the interaction with adhesion molecules on the surface of endothelium. These 
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reactions lead to activation of endothelium and attraction of immune cells [1]. 
Penetrating particles consist mainly of LDL, which are one of the targets of oxida-
tion and form oxLDL (oxidized LDL). oxLDLs are taken up by macrophages, which 
subsequently transform into the foam cells. Specific autoantibodies against oxLDL 
(anti-oxLDL) were detected in the sera of individuals from the general popula-
tion as well as in rheumatic patients [49]. Furthermore, in rheumatic patients, the 
levels of anti-oxLDL are increased compared to those in the general population 
[49, 50]. The presence of these antibodies can predict the peripheral vascular 
involvement and even the severity of ATS [51]. On the other hand, increased levels 
of anti-oxLDL antibodies in patients with pSS were paradoxically associated with 
decreased occurrence of plaques (unlike in RA or SLE), which suggests a possible 
protective role of anti-oxLDL antibodies in pSS [52].
Many autoantibodies have been described to have a relation to higher risk of ATS 
and its clinical manifestations [2]. These include the antibodies against heat shock 
proteins (HSPs), which are expressed on the surface of endothelial cells exposed to 
stress, and to β-2-glycoprotein I (β2GPI), which are abundantly expressed within 
the subendothelial layer and intima-media borders of plaques [46, 53]. Furthermore, 
antinuclear antibodies (ANAs) are more frequently detected in patients with symp-
tomatic angina pectoris and the three-vessel disease compared to individuals without 
coronary artery involvement [54]. Moreover, ANA positivity is associated with an 
increased risk of myocardial infarction (MI) in non-rheumatic individuals [55]. 
Specific anti-endothelial cell antibodies (AECAs) are associated with subclinical or 
manifested ATS in non-rheumatic population, as well [56].
2.5 Immunosuppressive therapy and its effect on CV risk
Immunosuppressive therapy of rheumatic diseases has a potential effect on CV 
morbidity and mortality in two ways: on the one hand, it suppresses the inflammatory 
activity and thus decreases the CV risk; on the other hand, the adverse effect of 
some drugs can worsen the CV risk [9, 57]. NSAIDs and coxibs (selective blockers 
of cyclooxygenase-2) mostly used in inflammatory arthropathies exert pro-throm-
botic effect and have a negative impact on the CV risk. Due to this fact, benefit-risk 
ratio should be evaluated individually in every case. Naproxen is considered as the 
relatively safest drug from this group [58].
Corticosteroids (CSs) suppress the inflammatory activity, hence dampen the CV 
risk [59, 60]. On the other hand, CSs cause or worsen the traditional CV risk factors 
[61]. Meta-analysis evaluating CS therapy in RA reported that a long-term therapy with 
prednisone or prednisone-equivalents in high doses (above 7.5 mg per day) is associated 
with an increased risk of CV mortality [62]. The effect of lower doses (7.5–10 mg a day) 
is uncertain [63]. Duration and the cumulative dose of CS are considered as CV risk 
factors in SLE. Nevertheless, current evidence regarding the CS therapy in SLE is not 
conclusive [44]. European League Against Rheumatism (EULAR) recommends, espe-
cially in inflammatory arthropathies, to keep the glucocorticoid dosage to a minimum 
and to taper glucocorticoids in case of remission or low disease activity and to regularly 
check the reasons to continue glucocorticoid therapy [59].
The group of disease-modifying anti-rheumatic drugs (DMARDs) is a heteroge-
neous entity of medicaments with immunosuppressive effects of various specific-
ity: less specific conventional synthetic DMARDs (csDMARD), or more specific 
biologic (bDMARDs), biosimilar (bsDMARDs) or targeted synthetic molecules 
(tsDMARDs). The side effects differ within the whole group. csDMARDs have 
a potential to reduce atherogenesis and progression of ATS [64]. Thus, the early 
initiation of therapy with scDMARDs can prevent development of CVDs [65].
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Antimalarial drugs have been reported to act favorably on lipid and glucose 
metabolism, and in SLE patients, they have been described to reduce hypercholes-
terolemia, ATS and the risk of thrombosis [44, 66, 67]. In addition, hydroxychlo-
roquine (HCQ ) influences the production of cytokines, activation of T cells and 
monocytes via interaction with Toll-like receptor (TLR) signaling pathway, and 
attenuates the oxidative stress and endothelial dysfunction [68].
The effects of methotrexate (MTX) on the CV risk have been best studied in RA, 
in which the potential to reduce the risk of heart failure by half was demonstrated 
[69]. Moreover, MTX can decrease the mortality of RA patients caused by CVDs 
by 30% [70]. The data suggest that MTX should be considered cardioprotective 
in rheumatic diseases, although the exact mechanism of this effect is not known 
yet [71]. A possible link with anti-inflammatory effect has been proposed [72]. On 
the other hand, according to the results of a recent randomized controlled trial in 
patients with carotid artery disease or history of MI and concurrent T2DM or MetS, 
no protective effect of MTX in low doses (15–20 mg weekly) on future risk of CVD 
was described [73]. Data in other DMARDs are insufficient and, therefore, the 
effect on CV risk is not clear.
bDMARDs are targeting selectively specific pro-inflammatory molecules, 
which significantly participate in both pathogenesis of inflammatory diseases and 
atherogenesis (e.g., TNF, IL-1r, IL-6 and others) [74]. In this group, TNF inhibitors 
(anti-TNFs) are the best-studied drugs regarding the possible effect on the CV risk. 
On the one hand, they exert anti-inflammatory and anti-atherogenic effect; on 
the other hand, they have been demonstrated to worsen the cardiac insufficiency 
in a couple of first published studies [3, 8]. Their benefit was proven in several 
randomized controlled trials (RCTs) with more or less significantly beneficial 
effect when compared to MTX [72, 75–77]. Anti-TNFa influences particularly the 
level of HDL and restores its anti-atherogenic potential [78]. The results of RCTs 
in RA, PsA and psoriasis show a beneficial effect of anti-TNF therapy on glucose 
metabolism and MetS [79]. Anti-TNFs also reduce the risk of T2DM manifesta-
tion and prevent endothelial damage due to specific inhibition of TNF [74, 80]. 
Overall, current data support the beneficial effect of anti-TNF therapy on CV risk 
and CVD incidence that is probably related to the attenuation of inflammation 
and thus also of atherogenesis rather than to the effect on lipidogram (which can 
change as a consequence of changes in disease activity as well). Published studies 
have reported the potential of anti-TNF to reduce intima-media thickness and the 
number of unstable plaques [81]. Nevertheless, anti-TNF therapy is not recom-
mended in patients with congestive heart failure [82]. Not only no positive effect, 
but even a negative effect of anti-TNF on chronic heart failure has been described. 
Experts therefore suggest performing a baseline echocardiography examination in 
patients at risk before the commencement of anti-TNF therapy [81].
Higher IL-6 levels are associated with an increased CV risk, therefore therapeu-
tic blockade of tocilizumab (inhibitor of IL-6 receptor) has a protective potential 
[83]. Recently published RCT with tocilizumab and etanercept (anti-TNF) reported 
very similar effect of both drugs on CV risk [84]. Inhibition of the IL-6 receptor by 
tocilizumab is assumed to influence lipid metabolism in a favorable manner due to 
blockade of the mobilization of fatty acids to peripheral tissues mediated by IL-6 
[84]. On the contrary, anti-IL-6r therapy is known to cause a significant increase in 
the levels of HDL, TC, LDL and TG [85].
Rituximab (RTX, anti-CD20) is supposed to have a beneficial effect on CV risk 
due to inhibition of B cells and release of (auto)antibodies, which participate in the 
vasoconstriction, activation of thrombocytes and promote rupture of atherosclerotic 
plaques [74]. In SLE patients, the RTX therapy was associated with improvement of 
lipidogram [86]. The overall effect of RTX on CV risk is not clear, due to limited data 
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and lack of SLE patients treated by RTX [44]. To date, studies with RTX have not 
shown any long-term adverse cardiovascular effects or cardiotoxicity [74, 87].
The recent study CANTOS (Canacinumab Antiinflammatory Thrombosis 
Outcome Study) has proven the ability of anti-IL-1b (canacinumab) to reduce the 
CV events and stroke in non-rheumatic patients with history of MI [88]. The effect 
of bDMARDs, including the latest bsDMARDs and tsDMARDs, on the CV risk 
needs to be closely monitored and evaluated in long-term studies with sufficiently 
large cohorts of rheumatic patients.
3. Atherosclerosis and its manifestation in rheumatic diseases
3.1 Rheumatoid arthritis
RA is relatively the most common autoimmune disease with prevalence of 1%, 
which primarily affects joints and can also manifest by extra-articular involvement. 
The most frequent occurrence of RA is in middle-aged women. It can shorten the 
life expectancy by up to 2.5 years [89, 90]. In addition, there is up to three times 
higher mortality in RA patients compared to the general population [91]. CV 
involvement and complications, including asymptomatic heart failure or silent 
MI and sudden death, are the leading death causes in RA patients and occur in RA 
patients 1.5 times more often than in the general population [2, 92]. CV risk in RA is 
comparable to the risk in diabetes [93].
The underlying mechanism of increased CV mortality in RA is not completely 
understood [94]. The main cause of death in RA is ischemic heart disease (IHD), 
often asymptomatic and underdiagnosed [91, 95, 96]. Up to three times increased 
risk of IHD in RA patients with positivity of anti-cyclic citrullinated peptide 
(aCCP) antibodies and rheumatoid factor (RF) has been reported [69, 97].
In fact, RA itself can act as an independent risk factor for development of CVD 
[98]. The relation between an increase in the CV risk and the disease duration of RA 
patients is partly attributable to a higher prevalence of hypertension and smoking [99]. 
In RA, CV risk is also significantly related to traditional risk factors [100]. Smoking has 
a negative impact on the course of RA and stimulates the production of RF and aCCP 
nevertheless, the direct role in the increase of CV risk was not proved [98, 101].
Systemic inflammation accompanying the activity of RA significantly contrib-
utes to the atherogenesis and CV mortality [102]. The reduction of CV risk was 
observed during the DMARD therapy (namely HCQ , MTX, anti-TNFs). According 
to available studies and their meta-analysis, CV risk is most increased by CS therapy 
(up to 47%) and NSAIDs, in particular by coxibs (by 36%), and, on the contrary, is 
decreased by MTX (by 28%) or anti-TNF therapy (by about 30%) [72].
3.2 Ankylosing spondylitis
AS is a chronic inflammatory disease, which primarily affects the joints in the 
site of enthesis. It belongs to the group of diagnostic entity called spondyloarthrop-
athies, which typically manifest in HLA-B27 positive patients. Similar to RA, AS can 
also manifest with extra-articular manifestations, such as gastrointestinal, ocular 
and cardiac involvement. The prevalence of AS in the population is about 0.1% (the 
overall prevalence of spondyloarthritis is around 1%) and, unlike most rheumatic 
diseases, occurs more frequently in men (up to three times) [103].
Similar to RA, an increased CV risk has been reported in AS patients [104, 105]. 
However, views on the close association of ATS and AS are divergent, in particular, due 
to the small evidence and conflicting results of studies [106]. Regarding the evidence 
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on CV events in AS, the situation is similarly unsatisfactory and inconclusive [107–109]. 
Recently published meta-analysis has reported an increased risk of MI (RR = 1.6) and 
cerebrovascular events (RR = 1.5) compared to the general population [110].
There are several risk factors in AS, which participate in CV comorbidities. Since 
laboratory markers of inflammation are not elevated in many patients, CV risk is likely 
related to the risk profile of a typical patient with AS: a smoker with arterial hyperten-
sion and dyslipidemia, in whom low levels of HDL and TC accompany the disease 
activity [105, 110]. In addition, extra-articular cardiac manifestations of AS (e.g., 
conduction disorders, aortic valve insufficiency, left ventricular dysfunction) contrib-
ute to CV morbidity and mortality [105]. Levels of C-reactive protein (CRP), therapy 
with NSAIDs and work disability are considered significant predictive factors of CV 
mortality in AS [111, 112]. NSAIDs as the first-line therapy with the highest safety 
profile should be prescribed for the shortest time period possible [110]. On the other 
hand, anti-TNFs have a favorable effect on the endothelial function and a decrease of 
the CV risk [105, 113].
3.3 Psoriatic arthritis
PsA is a systemic inflammatory disease from the spondyloarthritis spectrum, 
associated with psoriasis [114]. The prevalence is 0.05–0.25% in the general 
population, but rises to 15–30% in patients with psoriasis [115]. The relative risk 
of CV involvement in psoriasis is reported to be 1.4, but the relative risk in PsA is 
less studied and the data are conflicting [116–119]. Meta-analysis demonstrated a 
1.43 fold higher CV risk in PsA patients compared to the general population. The 
incidence of MI, cerebrovascular events and heart failure has been reported to be 
increased (1.68, 1.22 and 1.31, respectively) [120].
According to the current evidence, various manifestations of ATS in PsA have been 
described, from subclinical involvement to symptomatic manifestations [121–125]. 
PsA is considered to be an additional independent CV risk factor, as proved by findings 
of more severe subclinical ATS compared to the general population and the association 
of plaque development with the inflammatory activity of PsA [120].
PsA is typically associated with high prevalence of MetS, which is two or three 
times more common than in other rheumatic diseases and the general population 
[126]. During the active inflammatory phase, there are characteristic alterations of 
lipidogram with a decrease of HDL and LDL, which consequently rises in remis-
sion of the disease [9]. The suggested mechanism, which causes changes of HDL 
levels, is the uptake of apoA-1 in the tissue affected by inflammation: particles of 
HDL penetrate from the circulation due to increased endothelial permeability. The 
consequent decline of serum HDL concentrations increases the CV risk in PsA in a 
similar manner as in RA [127].
The presence of subclinical ATS and its correlation with inflammatory markers 
and the effect of immunosuppressive therapy are questionable [9, 128]. Anti-TFN 
therapy seems to have a beneficial effect on CV risk in PsA, as well as in AS [129].
3.4 Systemic lupus erythematosus
SLE is characterized by a wide spectrum of clinical manifestations and 
involvement of different organs. The prevalence is 0.03% in Caucasian popula-
tion, while SLE affects predominantly women in reproductive years, in whom 
the clinically significant ATS is not usually found under normal circumstances 
[130]. Although the survival of SLE has significantly improved, thanks to new 
therapeutic options, it still remains 5–10 years shorter compared to the general 
population [131]. The rate of SLE-associated mortality has declined, but the rate 
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of CV complications, which are considered to be the leading cause of mortality 
in SLE nowadays and are responsible for 30% of deaths, has risen [131]. The 
bimodal mortality pattern describes two peaks of mortality in SLE population: the 
first peak represents death early in the course of the disease related to the disease 
activity and infectious complications, and the second peak refers to late death 
from the CV manifestations [132].
The prevalence of traditional risk factors is higher in SLE compared to the gen-
eral population [133]. In addition, SLE-related risk factors, including renal involve-
ment, apply in CV morbidity. The presence of SLE itself increases the risk of heart 
failure up to three times [134]. The clinical manifestation of ATS in SLE is predicted 
particularly by higher age at the onset of SLE, presence of arterial hypertension and 
hypercholesterolemia. Among others, the cumulative dose and the duration of CS 
therapy, long duration of SLE, and activity of immune system including autoanti-
bodies play significant role in ATS [2].
Due to their pathophysiologic mechanism both SLE and vasculitis predispose 
to the atherosclerotic involvement of coronary circulation [135]. Coronary artery 
disease affects 6–10% of SLE patients and the incidence is four to eight times higher 
than in the general population [136, 137].
Risk of heart failure in SLE significantly rises immediately after the first mani-
festation of the autoimmune disorder, mostly at a young age. The relative risk of 
heart failure is therefore most increased in young patients in the age between 20 and 
30 years, and decreases with a higher age. However, the incidence of CV diseases 
and heart failure is continually increasing in positive correlation with the increas-
ing age of patients [134]. SLE patients are at 5–10 times higher risk, and young SLE 
women at age around 40 years are even at 50 times higher risk of MI compared to 
the general population [138].
Concerning the risk of a stroke in SLE, the ischemic stroke is estimated to be 
two times, hemorrhagic stroke three times and subarachnoid hemorrhage four 
times more common in SLE than in the general population [139]. In case of a stroke, 
young patients are more threatened due to accelerated ATS during the high activity 
of inflammation. The relation between disease activity and the risk of a stroke was 
described also in other diseases. Immunosuppressive therapy and other comorbidi-
ties (e.g., vasculitis, antiphospholipid syndrome, arterial hypertension) take part 
in this increased risk, as well [139]. Accompanying factors such as antiphospholipid 
syndrome, Liebman-Sacks endocarditis and formation of immune complexes of 
antibodies with antigens predispose patients to thrombotic complications and 
ischemic stroke, while endothelial dysfunction and interrupted endothelial layer 
integrity can lead to hemorrhagic stroke. Subarachnoid hemorrhage in SLE proba-
bly results from intracerebral vasculitis and concurrent arterial hypertension [139].
Atherosclerotic plaques have been detected in 17–65% of SLE patients using 
ultrasound examination. The age seems to play a major role in prediction of athero-
sclerosis and its manifestations in SLE. Some experts suggest a role of consequences 
of the disease activity and side effects of therapy in older patients with SLE [2].
3.5 Systemic sclerosis
SSc belongs to orphan connective tissue diseases with the prevalence of 0.003–
0.06%, and is less understood, concerning the CV risk. The key pathologies leading 
to CV involvement are vasculopathy, inflammation and tissue fibrosis, which can 
also affect the heart. In addition to pathognomic microvasculopathy, macrovascular 
involvement is getting more attention in the last years [45].
To date, the relative risk of CV diseases in SSc in not known. Survival of SSc 
patients is about 16–34 years shorter compared to the general population with about 
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3.5 times higher mortality [140]. Due to advances in therapy of scleroderma renal 
crisis (SRC) and pulmonary arterial hypertension (PAH), new causes of death have 
got to the front, and the prevalence of ATS in SSc has risen [141]. Cardiac causes 
account for a quarter of the overall mortality in SSc patients [142]. The prevalence 
of traditional CV risk does not seem to differ from the general population. SSc-
associated factors, which participate in endothelial damage, include inflammation 
and ischemia-reperfusion injury caused by impaired vasodilation [45]. The level 
of inflammation in SSc is lower than in RA or SLE, which indicates lower rate of 
acceleration of ATS. Impaired vasodilation characteristic for both SSc and ATS 
precedes the clinical manifestation of SSc. It is accompanied by the mechanisms 
typical for both of these pathologies: imbalance between vasodilators (e.g., nitric 
oxide, NO) and vasoconstrictors (e.g., endothelin), defective angiogenesis caused 
by the increased expression of VEGF, the presence of AECA and others. The main 
clinical manifestations of microvascular impairment, Raynaud’s phenomenon, PAH 
and SRC, probably predict macrovascular impairment in SSc [45].
Reports on the prevalence of ATS and its clinical manifestations in SSc differ 
in various studies. Among others, the reason is asymptomatic subclinical car-
diac involvement. Increased risk of CV events is attributed both to ATS and the 
pathogenesis of SSc and its consequences (impaired microcirculation, myocardial 
fibrosis, arrhythmia, etc.), and last but not least, secondary deterioration of cardiac 
function due to renal vasculopathy, interstitial lung disease (ILD) and PAH [143].
The risk of MI is almost 2.5 times higher compared to the general population, 
while the impact of SSc itself outweighs the effect of hypertension or diabetes on the 
risk of MI. Ischemic injury of myocardium can be caused by occlusive vasculopathy 
and intermittent vasospasm (so-called myocardial Raynaud’s phenomenon) [144].
It is not clear whether the prevalence of subclinical ATS in SSc is higher com-
pared to the general population. Nussinovitch and Shoenfeld reported carotid 
involvement in more than 60% of SSc patients, where the findings were described 
to be more frequent and more severe than in a control group from the general 
population [143].
Cerebrovascular involvement in SSc patients is 1.3 times more common than 
in the general population. SSc as an independent risk factor increases the risk of 
ischemic stroke by up to 43%. There are several pathologic mechanisms in SSc play-
ing a role in the manifestation of a stroke, including vasospasm of cerebral arteries 
corresponding to the Raynaud’s phenomenon, which can manifest as a transient 
ischemic attack or a focal neurologic deficit [145].
3.6 Idiopathic inflammatory myopathies
IIM is a heterogeneous group of diseases, which primary affect the skeletal 
muscles as the common pathologic mechanism. The most prevalent subtypes are 
dermatomyositis (DM) and polymyositis (PM) [146, 147]. IIM belongs to orphan 
rheumatologic diseases and occurs in approximately 0.02% of population [148]. 
The mortality in IIM is almost four times higher than in the general population, 
with CV involvement as the leading cause [149]. The main pathology responsible 
for the cardiac involvement in IIM is myocarditis and accelerated ATS in coronary 
arteries [150]. Other mechanisms have not been sufficiently studied. Resulting 
structural alterations in myocardium can lead to disturbed function, arrhythmia 
and other, mostly asymptomatic, rarely fatal manifestations [151].
Data on cardiovascular disability in IIM are insufficient. Meta-analysis of 
studies in IIM reported 2.24 times higher CV risk compared to the general popu-
lation [152]. With regard to the prevalence of MI in IIM, there are only limited 
data. A retrospective study by Rai et al. in more than 700 IIM patients described 
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an increased risk of MI, but not of a stroke. The risk of MI has been increased in 
PM almost four times and in DM three times compared to the general population. 
Patients were most threatened by these complications during the first years after 
the onset of IIM [153].
Traditional risk factors in IIM are specifically related to the specific features of 
the disease, particularly muscle involvement resulting in impaired physical activity 
and CS therapy. The prevailing effect of CS in IIM, whether anti-inflammatory or 
pro-atherogenic, is not clear and has yet to be elucidated [152].
3.7 Primary Sjögren’s syndrome
Primary Sjögren’s syndrome is another relatively rare rheumatic disease with 
a prevalence of 0.06%. It is characterized by lymphocytic infiltration of exocrine 
glands (especially lacrimal and salivary) leading to dryness of the mucous mem-
branes (sicca syndrome) and hyperactivity of B lymphocytes. pSS affects preferen-
tially females at the age of 40–60 years [154].
The situation in terms of the CV risk in pSS is similarly unclear as in the 
above-mentioned rare systemic connective tissue diseases [155]. There is a lack 
of studies concerning the CV risk in pSS, moreover, the results are conflicting. 
CVD-associated mortality accounts for 30% of deaths. According to the recent 
meta-analysis including 14 studies in pSS, the CV risk is significantly increased 
compared to the general population: the relative risk of coronary artery disease is 
1.34, cerebrovascular events 1.46, heart failure 2.54 and thromboembolism 1.78. 
This meta-analysis has not demonstrated a significantly increased risk of mortality 
due to CV causes (RR = 1.48) [155].
Similar results have been reported in a population study that also described 
higher prevalence of arterial hypertension and hypercholesterolemia in pSS 
patients, and, in addition, suggested pSS as an independent CV risk factor [156]. 
On the other hand, some studies did not confirm the increased CV risk in pSS 
[157, 158]. One study has reported subclinical atherosclerotic involvement in 
pSS patients detected by coronary flow reserve (CFR) and pulse wave velocity 
(PWV), while the echocardiography showed no pathology [159]. Impaired PWV 
is thus suggested as a marker of endothelial dysfunction even in patients with 
normal CFR [160].
Available data rather suggest higher CV risk in pSS patients compared to the 
general population, and the need of preventive screening and appropriate manage-
ment, eventually including consultation and monitoring by a cardiologist [155].
4. Examination and estimation of the CV risk
Chronic inflammatory condition can skew the results of the examination, which 
have otherwise good reliability in the general population [3]. For example, ultra-
sound imaging of clinically insignificant atherosclerotic lesions or plaques cannot 
reveal the higher susceptibility to the progression and rupture of plaques in the 
inflammatory environment [5]. Several scoring systems were developed to facilitate 
the estimation of the CV risk in the general population. These scoring systems 
include particularly the traditional risk factors. The most used and widespread 
systems are Framingham Risk Score (FRS), Systemic Coronary Risk Evaluation 
(SCORE), QResearch Risk Score (QRISK2, or rather its updated version QRISK 3),  
Reynolds Risk Score and many others [161, 162]. FRS was the first developed 
scoring system and served as a default model for creating newer scoring systems. 
Nowadays, SCORE is probably the most used and widespread scoring system, 
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especially in Europe [163]. Above-mentioned classic scoring systems underestimate 
the CV risk in rheumatic patients and therefore are not suitable for estimating 
the CV risk in these patients. A certain compromise was made by developing the 
Reynolds Risk Score by inclusion of CRP value as a marker of inflammation, and 
QRISK2 by inclusion the presence of RA as an independent risk factor [161]. Based 
on the recent EULAR recommendations for management of the CV risk in inflam-
matory arthropathies published in 2016, a modified SCORE system (mSCORE) 
should be used for evaluation of the CV risk in RA patients, which is calculated by 
multiplying the standard calculated value by a coefficient of 1.5 in all RA patients 
[58]. Despite this modification, mSCORE is not completely reliable in estimation 
of the CV risk, as was shown in studies describing findings of subclinical ATS in 
rheumatic patients classified in the low-risk category according to the mSCORE, 
and the evidence of higher tendency to formation of ATS plaques and instability of 
these plaques in RA. Due to these reasons, EULAR proposed simultaneous regular 
non-invasive examination by ultrasound of carotids and/or measuring the ankle-
brachial index (ABI) for detection of subclinical ATS in asymptomatic patients in a 
low-risk category (SCORE 1–4%) [58, 82].
The CV risk should be assessed at least every 5 years in patients with low disease 
activity and should be reconsidered after major changes in therapy or progression 
of the disease [58, 59, 82]. In common practise, this assessment means regular 
examination of blood pressure and lipidogram during the outpatient control and in 
case of pathologic findings, early consultation by a preventive cardiologist and an 
adequate therapeutic intervention [62, 164].
5. Therapy
Preventive measures are the first-line therapy recommended in the general 
population to manage the CV risk. In rheumatic patients, these measures may be 
complicated due to a chronic disease. Therefore, the pharmacological treatment is 
needed [62, 82].
Metformin is recommended as the first line for the treatment of the MetS. It has 
a beneficial effect not only on improvement of insulin sensitivity, but also reduces 
the levels of LDL and TC and has a beneficial effect on the vascular function, as 
well as statins. Similar beneficial effect on glucose metabolism is related to admin-
istration of antimalarial drugs, which are often used in the treatment of SLE, pSS 
and also RA. HCQ exerts immunomodulatory and anti-inflammatory effect, and, 
in addition, induces an increase in insulin activity and serum levels of glucagon and 
improves the glucose tolerance. Moreover, HCQ reduces plasma glucose levels even 
in the general population and is therefore suitable as a part of MetS therapy [82]. 
Other drugs for glucose metabolism control include pioglitazone (a nuclear peroxi-
some proliferator-activated receptor-γ agonist), and liraglutide (glucagon-like 
peptide-1 analog), which has a beneficial effect in obese patients [13].
When managing and treating dyslipidemia, the recommended target 
levels of LDL (especially for RA) are lower than for the general population 
(LDL < 2.6 mmol/L; in individuals at higher risk, even <1.8 mmol/L). At the 
same time, preventive antiplatelet therapy should be considered [62]. Statins 
have been extensively discussed, especially in rheumatology. Via competitive 
inhibition of HMG-CoA (3-hydroxy-3-methyl-glutaryl-coenzym A) reductase, 
they inhibit the intermediate step in the synthesis of cholesterol. Despite the 
concerns of potential side effects as induction of immune-mediated necrotizing 
myopathy (IMNM), the use of statins in IIM patients does not seem to be more 
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risky than in the general population [165]. Several studies demonstrated a ben-
eficial potential of statins to reduce the CV risk via attenuation of the oxidative 
stress and improvement of endothelial function. Due to their anti-inflammatory 
potential, statins are preferentially recommended in the therapy of rheumatic 
patients according to the EULAR recommendations [62]. For example, atorvas-
tatin, when administrated to RA patients, not only reduces the levels of TC and 
LDL, but apparently also inhibits the inflammation activity [166]. This favorable 
effect was confirmed in TRACE-RA study [167]. Rosuvastatin exerts a similar 
beneficial effect in inflammatory joint diseases [168]. Another therapeutic 
option for dyslipidemia treatment is fenofibrate, which increases the HDL levels, 
and niacin [13].
Regarding the management of arterial hypertension, targeting the optimal 
blood pressure is more important than considering the type of drug used in therapy 
[58]. ACE inhibitors or blockers of AT1 receptor for angiotensin II exert a poten-
tial anti-inflammatory effect similar to statins, and therefore are preferentially 
recommended for treatment of arterial hypertension [62]. There is an exception 
in SSc patients. ACE inhibitors are recommended in the treatment of manifested 
SRC, but not as a prevention of SRC. Thus, other antihypertensive drugs should be 
prescribed (if SRC is not present), especially calcium channel blockers due to their 
beneficial effect on Raynaud’s phenomenon [169].
Among other drugs with beneficial effect, vitamin D should not be forgotten. It 
was demonstrated that vitamin D acts as an immunomodulator and probably plays 
a protective role in the development of CV diseases, insulin resistance and obesity, 
and has anti-inflammatory effect and can potentially prevent from the development 
of MetS in RA patients. Also, probiotics are worth mentioning. Based on the results 
of studies showing that adverse changes of gut microbiome can induce autoimmune 
disorders, administration of probiotics may be profitable, as this could prevent the 
development of autoimmune disease or mitigate the consequences of already pres-
ent pathological metabolic changes. However, further studies are needed to confirm 
these hypotheses [13].
Finally, the other side of this issue must not be forgotten, that is, adequate anti-
inflammatory therapy of rheumatic diseases using DMARDs (especially MTX and 
TNF inhibitors in RA). Such therapy leads to mitigation of inflammatory activity 
and also improvement of quality of life and fitness of patients. Better fitness enables 
physical activity and thus facilitates the elimination of traditional risk factors and 
thereby reduces the CV risk [13].
6. Conclusion
Rheumatic patients are significantly more at risk of atherosclerosis and its com-
plications than individuals from the general population. Traditional risk factors are 
in rheumatic patients more frequent. Moreover, these risk factors are often hard to 
manage by modification of life style. Nowadays, a wide range of therapeutic options 
is available for elimination of traditional risk factors and reduction of the cardio-
vascular risk. The appropriate anti-inflammatory therapy represents the golden 
standard. Despite the growing evidence on the cardiovascular risk in rheumatic 
patents, the adequate recommendations for management of these patients and 
early detection of a higher risk are still lacking. The task for the future is to create 
an examination algorithm to prevent underestimation and negligence of risk in 
rheumatic patients and also to extend the knowledge on the cardiovascular risk in 
rare rheumatic diseases.
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